Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
2.

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine.

Vera J, Paludo J, Kottschade L, Brandt J, Yan Y, Block M, McWilliams R, Dronca R, Loprinzi C, Grothey A, Markovic SN.

Support Care Cancer. 2019 Feb 14. doi: 10.1007/s00520-019-4654-2. [Epub ahead of print]

PMID:
30767130
3.

Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study.

Monfort SM, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419828823. doi: 10.1177/1534735419828823.

PMID:
30741022
4.

NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djz011. [Epub ahead of print]

PMID:
30715378
5.

A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, Loprinzi CL.

J Palliat Care. 2019 Feb 3:825859719827589. doi: 10.1177/0825859719827589. [Epub ahead of print]

PMID:
30714486
6.

Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.

Smith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, Le-Rademacher J, Yang JJ.

Support Care Cancer. 2018 Nov 20. doi: 10.1007/s00520-018-4553-y. [Epub ahead of print]

PMID:
30460399
7.

Rose geranium in sesame oil nasal spray: a treatment for nasal vestibulitis?

Cathcart-Rake EJ, Smith D, Zahrieh D, Loprinzi CL.

BMJ Support Palliat Care. 2018 Sep 26. pii: bmjspcare-2018-001569. doi: 10.1136/bmjspcare-2018-001569. [Epub ahead of print]

PMID:
30377210
8.

Building a Cardio-Onco-Hematology Program.

Herrmann J, Loprinzi C, Ruddy K.

Curr Oncol Rep. 2018 Sep 10;20(10):81. doi: 10.1007/s11912-018-0725-7. Review.

PMID:
30203261
9.

Apixaban and dalteparin in active malignancy associated venous thromboembolism.

McBane R 2nd, Loprinzi CL, Ashrani A, Botero JP, Leon Ferre RA, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE.

Thromb Haemost. 2017 Oct;117(10):1952-1961. doi: 10.1160/TH17-03-0193. Epub 2017 Nov 28.

PMID:
30151821
10.

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.

Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R.

Neurology. 2018 Aug 28;91(9):403-413. doi: 10.1212/WNL.0000000000006083. Epub 2018 Jul 27. Review.

PMID:
30054438
11.

Updates in the Evaluation and Management of Breast Cancer.

O'Sullivan CC, Loprinzi CL, Haddad TC.

Mayo Clin Proc. 2018 Jun;93(6):794-807. doi: 10.1016/j.mayocp.2018.03.025. Review.

PMID:
29866283
12.

Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?

Cathcart-Rake E, Smith D, Zahrieh D, Jatoi A, Yang P, Loprinzi CL.

Support Care Cancer. 2018 Nov;26(11):3909-3914. doi: 10.1007/s00520-018-4261-7. Epub 2018 May 24.

PMID:
29797079
13.

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.

Smith TJ, Loprinzi CL, Deville C.

N Engl J Med. 2018 May 3;378(18):1745-1746. doi: 10.1056/NEJMc1801992. No abstract available.

PMID:
29719180
15.

Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism.

Simmons B, Wysokinski W, Saadiq RA, Bott-Kitslaar D, Henkin S, Casanegra A, Lenz C, Daniels P, Bjarnason H, Vargas E, Hodge D, Holton SJ, Cerhan JR, Loprinzi C, McBane R 2nd.

Eur J Haematol. 2018 Apr 4. doi: 10.1111/ejh.13074. [Epub ahead of print]

PMID:
29617053
16.

Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy.

O'Sullivan CC, Van Houten HK, Sangaralingham LR, Leal AD, Shinde S, Liu H, Ettinger D, Loprinzi CL, Ruddy KJ.

J Natl Compr Canc Netw. 2018 Mar;16(3):294-299. doi: 10.6004/jnccn.2017.7043.

PMID:
29523668
17.

Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort.

Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP.

J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):636-641. doi: 10.1136/jnnp-2017-317215. Epub 2018 Feb 8.

18.

Supplements to Help Prevent Neuropathy During Chemotherapy? A Cautionary Tale.

Giridhar KV, Viscuse PV, Loprinzi CL, Ruddy KJ.

J Natl Cancer Inst. 2018 Jun 1;110(6):551-552. doi: 10.1093/jnci/djx294. No abstract available.

PMID:
29361012
19.

Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).

Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, Sood R, Griffin P, Terstriep SA, Mattar B, Lafky JM, Loprinzi CL.

Support Care Cancer. 2018 Apr;26(4):1335-1343. doi: 10.1007/s00520-017-3960-9. Epub 2017 Nov 21.

PMID:
29164377
20.

Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.

Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro CL, Yee L.

Breast Cancer Res Treat. 2018 Feb;167(3):709-718. doi: 10.1007/s10549-017-4559-z. Epub 2017 Nov 3.

21.

Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.

Leal AD, Van Houten H, Sangaralingham L, Freedman RA, Jemal A, Neuman HB, Haddad TC, Mutter RW, Keegan THM, Mougalian SS, Loprinzi CL, Gross CP, Shah N, Ruddy KJ.

Clin Breast Cancer. 2018 Aug;18(4):e513-e520. doi: 10.1016/j.clbc.2017.09.011. Epub 2017 Sep 22.

22.

Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).

Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, Terstriep SA, Rana FN, Dockter T, Atherton PJ, Tsai M, Sturtz K, Lafky JM, Riepl M, Thielen J, Loprinzi CL.

Support Care Cancer. 2018 Feb;26(2):643-650. doi: 10.1007/s00520-017-3878-2. Epub 2017 Sep 18.

23.

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline.

Gilligan T, Coyle N, Frankel RM, Berry DL, Bohlke K, Epstein RM, Finlay E, Jackson VA, Lathan CS, Loprinzi CL, Nguyen LH, Seigel C, Baile WF.

J Clin Oncol. 2017 Nov 1;35(31):3618-3632. doi: 10.1200/JCO.2017.75.2311. Epub 2017 Sep 11. Review.

PMID:
28892432
24.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

25.

Thalidomide: Rebirth of a Gestational Antiemetic?

Ruddy KJ, Navari RM, Loprinzi CL.

J Clin Oncol. 2017 Nov 1;35(31):3523-3524. doi: 10.1200/JCO.2017.74.9663. Epub 2017 Sep 5. No abstract available.

PMID:
28872926
26.

Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.

McBane Ii R, Loprinzi CL, Ashrani A, Perez-Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE.

Thromb Haemost. 2017 Oct 5;117(10):1952-1961. doi: 10.1160/TH17-03-0193. Epub 2017 Aug 24.

PMID:
28837207
27.

Scrambler Therapy for the Treatment of Chronic Post-Mastectomy Pain (cPMP).

Smith T, Cheville AL, Loprinzi CL, Longo-Schoberlein D.

Cureus. 2017 Jun 21;9(6):e1378. doi: 10.7759/cureus.1378.

28.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
29.

Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS.

Support Care Cancer. 2017 Nov;25(11):3537-3544. doi: 10.1007/s00520-017-3780-y. Epub 2017 Jun 20.

30.

A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.

Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, Lafky JM, Dentchev T, Le-Lindqwister NA, Sikov WM, Staff N, Beutler AS, Loprinzi CL.

Support Care Cancer. 2017 Nov;25(11):3407-3416. doi: 10.1007/s00520-017-3760-2. Epub 2017 May 27.

PMID:
28551844
31.

Zoledronic Acid Dosing Interval for Metastatic Cancer-Reply.

Himelstein AL, Loprinzi CL, Shapiro CL.

JAMA. 2017 Apr 11;317(14):1478. doi: 10.1001/jama.2017.2566. No abstract available.

PMID:
28399247
32.

Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.

Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, Loprinzi CL, Chaudhari AMW, Lustberg MB.

Breast Cancer Res Treat. 2017 Jul;164(1):69-77. doi: 10.1007/s10549-017-4230-8. Epub 2017 Apr 3.

33.

Chemotherapy-induced neuropathy: Central resolution of a peripherally perceived problem?

Cathcart-Rake EJ, Hilliker DR, Loprinzi CL.

Cancer. 2017 Jun 1;123(11):1898-1900. doi: 10.1002/cncr.30650. Epub 2017 Mar 3. No abstract available.

34.

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.

JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.

35.

Management of hot flashes in women with breast cancer receiving ovarian function suppression.

Leon-Ferre RA, Majithia N, Loprinzi CL.

Cancer Treat Rev. 2017 Jan;52:82-90. doi: 10.1016/j.ctrv.2016.11.012. Epub 2016 Dec 5. Review.

PMID:
27960127
36.

New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment.

Majithia N, Loprinzi CL, Smith TJ.

Oncology (Williston Park). 2016 Nov 15;30(11):1020-9. Review.

37.

Fit for Chemo: Nerves May Thank You.

Leon-Ferre R, Ruddy KJ, Staff NP, Loprinzi CL.

J Natl Cancer Inst. 2016 Oct 28;109(2). pii: djw208. Print 2017 Feb. No abstract available.

PMID:
27794125
38.

Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).

Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL.

Support Care Cancer. 2016 Dec;24(12):5059-5068. Epub 2016 Aug 18.

39.

Olanzapine for Chemotherapy-Induced Nausea and Vomiting.

Navari RM, Loprinzi ChL.

N Engl J Med. 2016 Oct 6;375(14):1396. doi: 10.1056/NEJMc1610341. No abstract available.

PMID:
27705262
40.

Management of Hormone Deprivation Symptoms After Cancer.

Faubion SS, Loprinzi CL, Ruddy KJ.

Mayo Clin Proc. 2016 Aug;91(8):1133-46. doi: 10.1016/j.mayocp.2016.04.009. Review.

PMID:
27492917
41.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL.

N Engl J Med. 2016 Jul 14;375(2):134-42. doi: 10.1056/NEJMoa1515725.

42.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

43.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

44.

N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.

Miller RC, Petereit DG, Sloan JA, Liu H, Martenson JA, Bearden JD 3rd, Sapiente R, Seeger GR, Mowat RB, Liem B, Iott MJ, Loprinzi CL; Alliance for Clinical Trials in Oncology.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1168-74. doi: 10.1016/j.ijrobp.2016.01.063. Epub 2016 Apr 23.

45.

Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study.

Monfort SM, Pan X, Patrick R, Singaravelu J, Loprinzi CL, Lustberg MB, Chaudhari AMW.

Gait Posture. 2016 Jul;48:237-242. doi: 10.1016/j.gaitpost.2016.06.011. Epub 2016 Jun 14.

46.

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting.

Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL.

J Community Support Oncol. 2016 Apr;14(4):141-7. doi: 10.12788/jcso.0245.

PMID:
27152512
47.

Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.

Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A.

Lancet Oncol. 2016 May;17(5):663-70. doi: 10.1016/S1470-2045(16)00038-3. Epub 2016 Apr 12.

48.

Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]).

Sio TT, Atherton PJ, Birckhead BJ, Schwartz DJ, Sloan JA, Seisler DK, Martenson JA, Loprinzi CL, Griffin PC, Morton RF, Anders JC, Stoffel TJ, Haselow RE, Mowat RB, Wittich MA, Bearden JD 3rd, Miller RC.

Support Care Cancer. 2016 Sep;24(9):3847-55. doi: 10.1007/s00520-016-3213-3. Epub 2016 Apr 14.

49.

Scrambler Therapy for the management of chronic pain.

Majithia N, Smith TJ, Coyne PJ, Abdi S, Pachman DR, Lachance D, Shelerud R, Cheville A, Basford JR, Farley D, O'Neill C, Ruddy KJ, Sparadeo F, Beutler A, Loprinzi CL.

Support Care Cancer. 2016 Jun;24(6):2807-14. doi: 10.1007/s00520-016-3177-3. Epub 2016 Apr 4. Review.

50.

Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.

Bott-Kitslaar DM, Saadiq RA, McBane RD, Loprinzi CL, Ashrani AA, Ransone TR, Wolfgram AA, Berentsen MM, Wysokinski WE.

Am J Med. 2016 Jun;129(6):615-9. doi: 10.1016/j.amjmed.2015.12.025. Epub 2016 Jan 18.

PMID:
26797081

Supplemental Content

Loading ...
Support Center